Demographic and clinical characteristics of patients who experienced a perforation with bevacizumab
| Characteristic | Patient 1 | Patient 2 |
|---|---|---|
| Age, yr | 68.6 | 55.2 |
| Sex | Male | Female |
| BMI | 20.9 | 18.8 |
| ECOG PS | 1 | 1 |
| Stage | Metastasis to liver and peritoneum | Metastasis to liver and peritoneum |
| CEA at initial diagnosis, μg/L | 3.9 | 3087 |
| Location of stricture | Sigmoid | Transverse colon |
| Primary in situ | Yes | Yes |
| Chemotherapy regimen | FOLFIRI-bevacizumab | FOLFIRI-bevacizumab |
| Timing of first chemotherapy | 79 d after stenting | 29 d after stenting |
| Time between stenting and perforation | 126 d | 40 d |
| Time between last chemotherapy and perforation | 5 d | 11 d |
| Outcome after perforation | Emergency surgery (diverting ileostomy); subsequently resumed chemotherapy | Patient died of intra-abdominal sepsis |
| Time from stenting to death | 488 d | 54 d |
BMI = body mass index; CEA = carcinoembryonic antigen; ECOG PS = Eastern Cooperative Oncology Group performance scale.